IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
IDEXX Laboratories's price to sales ratio was 12.2× on Nov 11, 2026, against 14.5× a year earlier. Over the last 5 years it ranged from 8.2× to 17.8×, with a median of 11.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.2× | −0.8 |
| 2025 | Dec 31, 2025 | 13.0× | +4.2 |
| 2024 | Dec 31, 2024 | 8.8× | −4.0 |
| 2023 | Dec 29, 2023 | 12.9× | +2.7 |
| 2022 | Dec 30, 2022 | 10.1× | −7.7 |
| 2021 | Dec 31, 2021 | 17.8× | +1.4 |
| 2020 | Dec 31, 2020 | 16.5× | +6.9 |
| 2019 | Dec 31, 2019 | 9.5× | +2.1 |
| 2018 | Dec 31, 2018 | 7.4× | +0.0 |
| 2017 | Dec 29, 2017 | 7.4× | +1.2 |
| 2016 | Dec 30, 2016 | 6.2× | +1.9 |
| 2015 | Dec 31, 2015 | 4.3× | −0.9 |
| 2014 | Dec 31, 2014 | 5.2× | +0.8 |
| 2013 | Dec 31, 2013 | 4.3× | +0.2 |
| 2012 | Dec 31, 2012 | 4.1× | +0.3 |
| 2011 | Dec 30, 2011 | 3.8× | −0.0 |
| 2010 | Dec 31, 2010 | 3.8× | +0.6 |
| 2009 | Dec 31, 2009 | 3.2× | – |
See a number that looks wrong?